Skip to main content
NovaBay Pharmaceuticals, Inc. logo

NovaBay Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · NBY ISIN · US66987P2011 LEI · 549300D5U7PQPNEX8Q38 US Manufacturing
Open in API
Filings indexed 1,026 across all filing types
Latest filing 2026-05-20 Earnings Release
Country US United States of America
Listing US NBY

About NovaBay Pharmaceuticals, Inc.

https://novabay.com/

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes scientifically-created and clinically-proven products for the eyecare, skincare, and wound care markets. The company's core technology is a proprietary, stable formulation of hypochlorous acid. Its leading product is Avenova®, an antimicrobial lid and lash solution available over-the-counter for eye hygiene. In the wound care sector, NovaBay manufactures and sells products under the NeutroPhase® and PhaseOne® brands, which utilize its hypochlorous acid technology to aid in cleansing and debridement. The company focuses on providing accessible, problem-solving solutions for improved well-being.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 85% confidence The document is a U.S. SEC Form 8-K filed by Stablecoin Development Corporation reporting results of operations for the quarter ended March 31, 2026 and furnishing the associated press release as Exhibit 99.1. Although presented on an 8-K, its primary content is the initial announcement of quarterly financial results (“Results of Operations and Financial Condition” Item 2.02 and the Regulation FD disclosure Item 7.01). Per the definitions, this constitutes an Earnings Release (ER) — the initial, summary announcement of periodical results. Q1 2026
2026-05-20 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
10-K/A - Stablecoin Development Corp (0001389545) (Filer)
Annual Report FY 2025
2026-04-29 English
8-K - Stablecoin Development Corp (0001389545) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and includes a press release about updated holdings and staking rewards. The document is short (3796 characters) and primarily announces a press release (Exhibit 99.1) rather than providing detailed financial statements or comprehensive analysis. It does not contain full financial data or detailed management discussion, but rather a furnished press release. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Interim Report. The confidence is high given the clear identification as a Form 8-K and the nature of the content.
2026-04-06 English
8-K - Stablecoin Development Corp (0001389545) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by NovaBay Pharmaceuticals, Inc. It includes detailed disclosures about the adoption of a new Equity Incentive Plan, employment agreements for executives, and amendments to the company's certificate of incorporation and bylaws, including a corporate name change. The content focuses on management and board decisions, executive compensation plans, and corporate governance changes. There are no financial statements or earnings data presented, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy solicitation or voting results announcement. It is not a regulatory certification or legal proceeding update. The primary focus is on management and board information, including director and officer changes and compensation arrangements. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (15,000 characters) and detailed content support a high confidence in this classification.
2026-04-01 English
8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes announcements of a company name change, ticker symbol change, and an update on holdings and staking rewards. It references a press release as an exhibit but does not contain detailed financial statements or comprehensive financial analysis. The document is primarily an announcement of corporate events and disclosures rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-03-23 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.